California Court orders in favor of Plexxikon in dispute with Novartis
Tokyo: Daiichi Sankyo has announced that the U.S. District Court for the Northern District of California has issued an order sustaining a jury verdict in favor of Plexxikon Inc. (its U.S. subsidiary whose offices closed in March 2022), on its claim that Novartis Pharmaceuticals Corporation's BRAF inhibitor Tafinlar infringes Plexxikon's U.S. Patents 9,469,640 and 9,844.539 ("the patents").
The case was filed by Plexxikon in August 2017. The order directs Novartis to pay $177.8 million in damages and a 9% royalty on U.S. sales of Tafinlar until the expiration of the patents of Plexxikon.
Read also: Novartis to take US drug patent case to Supreme Court
The Court reversed the jury's finding of willful infringement by Novartis. Any impact on Daiichi Sankyo's consolidated financials for fiscal year ending March 31, 2023, is currently being evaluated and will be announced as soon as possible.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.